SCHEDULE: Polar Capital Discloses 8.46% Stake in Enliven Therapeutics

Polar Capital Holdings Plc has filed a Schedule 13G reporting an 8.46% beneficial ownership stake in Enliven Therapeutics, Inc.

Summary

• Polar Capital Holdings Plc, along with its subsidiaries Polar Capital LLP and Polar Capital Funds PLC Biotechnology Fund, reported beneficial ownership of 5,056,807 shares of Enliven Therapeutics, Inc. common stock.
• This holding represents 8.46% of the company's total outstanding shares, based on 60,904,946 shares outstanding as of May 7, 2026.
• The reporting entities maintain sole voting and dispositive power over the entire 5,056,807 share position.
• The filing confirms the shares are held for investment purposes and not to influence or change control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive development, as it confirms significant institutional backing without indicating any immediate corporate distress or activist intervention.

Positives

• Institutional investor confidence is demonstrated by a significant 8.46% equity position held by a specialized biotechnology fund.
• The investment is classified as passive, indicating the firm's support for current management and strategic direction.

Negatives

• None identified; this is a standard regulatory disclosure of institutional shareholding.

Risks

• The investment is subject to the inherent volatility and clinical trial risks associated with the biotechnology sector.
• Future changes in the issuer's share count could dilute the percentage ownership held by the reporting entities.

Future Outlook

The filing does not provide forward-looking guidance for the issuer, as it is a disclosure of existing ownership status.

Industry Context

StockSavvy.ai notes that institutional accumulation of shares in clinical-stage biotechnology firms often signals long-term confidence in the company's pipeline and research progress, consistent with the investment mandate of specialized biotech funds.

Comparison to Industry Standards

• The 8.46% stake is a substantial position for a specialized biotechnology fund, aligning with typical institutional holding patterns for mid-cap biotech equities.
• The filing follows standard SEC Schedule 13G requirements for passive investors, consistent with industry practices for asset managers like Polar Capital.

Stakeholder Impact

• Shareholders may view the disclosure of a large institutional position as a validation of the company's investment thesis.
• The passive nature of the holding suggests stability in the current shareholder base.

Next Steps

• The reporting entities are required to file amendments to this Schedule 13G if there are material changes in their percentage of ownership.

Key Dates

Keywords

Enliven Therapeutics, Polar Capital, Schedule 13G, Biotechnology, Institutional Ownership, Equity Disclosure